Ipsogen

Most random gene expression signatures are significantly associated with breast cancer outcome, according to a research team at Université Libre de Bruxelles.

Ipsogen's board has voted in favor of the deal, and shareholders holding 61 percent of Ipsogen's stock have agreed to sell their shares to Qiagen.

Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.

The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.

Qiagen has entered into exclusive negotiations to acquire 47 percent of Ipsogen's stock. After the completion of that deal, Qiagen would move to acquire all remaining shares of the French cancer molecular diagnostic firm.

Sysmex will distribute certain Ipsogen products in Japan and submit Ipsogen products for the diagnosis and monitoring of BCR-ABL and JAK2 to Japanese health authorities.

Product Watch

Premium

Agilent's SureSelect XT Mouse All Exon kit; NanoString's nCounter Mouse miRNA Expression kit; Ipsogen's BCR-ABL Mbcr IS-MMR kits; ATCC's Universal Mycoplasma Detection kit.

New Releases

Premium

Ipsogen's BCR-ABL Mbcr

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more